sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Global Neuroblastoma Drugs Market Size study, by Type (Chemotherapy, Immunotherapy, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Online, Offline), and Regional Forecasts 2024-2032

Global Neuroblastoma Drugs Market Size study, by Type (Chemotherapy, Immunotherapy,...

Home / Categories / Healthcare
Global Neuroblastoma Drugs Market Size study, by Type (Chemotherapy, Immunotherapy, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Online, Offline), and Regional Forecasts 2024-2032
Global Neuroblastoma Drugs Market Size...
Report Code
RO1/103/2952

Publish Date
30/Aug/2024

Pages
200
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
Global Neuroblastoma Drugs Market is valued approximately USD 740 million in 2023 and is anticipated to grow with a healthy growth rate of more than 6.2% over the forecast period 2024-2032. Neuroblastoma is a cancer primarily occurring in young children below five years old, originating in nerve tissue specifically in the adrenal glands atop the kidneys. It emerges from immature nerve cells, called neuroblasts, known for its diverse symptoms and outcomes. These range from abdominal lumps, altered bowel patterns, bone discomfort, fatigue, to skin alterations, showcasing its varied presentation. Neuroblastoma drugs are medications tailored to combat neuroblastoma. It encompasses chemotherapy agents like cisplatin and etoposide, targeted therapies such as crizotinib targeting the ALK gene, immunotherapies like dinutuximab, differentiation agents like retinoic acid, and radiopharmaceuticals like I-131 MIBG. Treatment plans are individualized based on factors like the cancer stage and patient's health involving a combination of therapies designed by a team of specialists to optimize effectiveness. The rising shift towards personalized medicine and targeted therapies is a key trend for the Global Neuroblastoma Drugs Market. Drug developers are concentrating more on creating medications that specifically target genetic abnormalities or biological processes associated with neuroblastoma. This method reduces adverse effects and enhances patient outcomes by enabling more focused and efficient therapy.

In addition, the key driving factors influencing the Neuroblastoma Drugs market include advancements in medical technology, leading to improved diagnosis and treatment options for neuroblastoma patients. Additionally, increased awareness about neuroblastoma and early detection initiatives contribute to the demand for neuroblastoma drugs. Moreover, ongoing research and development efforts focused on developing targeted therapies and immunotherapies further propel market growth. Pharmaceutical companies are heavily investing in research and development (R&D) of new neuroblastoma drugs to the unmet need for more effective treatments for this disease. As a result of this increased R&D activity, there are several new neuroblastoma drugs in the pipeline that have the potential to improve outcomes for patients. Furthermore, collaborations between pharmaceutical companies, academic institutions, and healthcare organizations foster innovation and the introduction of novel neuroblastoma drugs into the market, which are further presenting various growth prospects to the Global Neuroblastoma Drugs Market during the estimated period. However, adverse side effects associated with neuroblastoma drugs and stringent regulatory requirement for drug approvals are expected to stifle Global Neuroblastoma Drugs Market growth between 2022 and 2032.

The key regions considered for the global Neuroblastoma Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America held the dominant position in the neuroblastoma drugs market due to several factors such as rising availability of neuroblastoma drugs, supportive governmental initiatives, robust regulatory backing, and a well-established healthcare system. Moreover, the region benefits from the significant presence of key industry players that are actively engaged in strategic initiatives like product approvals and partnerships, contributing significantly to market expansion in North America. On the other hand, Asia Pacific is poised for rapid growth over the forecast period.

Major market player included in this report are:
Recordati Group
Eli Lilly and Company
Bristol-Myers Squibb Company
Y-mabs Therapeutics, Inc.
MacroGenics Inc.
AstraZeneca plc
United Therapeutics Corporation
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Cellectar Biosciences, Inc.
The detailed segments and sub-segment of the market are explained below:
By Type
Chemotherapy
Immunotherapy
Others
By Route of Administration
Oral
Injectable
By Distribution Channel
Online
Offline
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com